diazoxide choline ER

all catalysts(0)

nothing on the calendar yet

News(6)

• An AI drug specialist zeroes in on rare forms of obesity
  Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…
  biopharma_dive · 1mo ago
• Four questions on new safety warnings for Neurocrine’s Vykat XR
  A group of experts on Prader-Willi syndrome has sounded the alarm on side effects and deaths that may be connected to Neurocrine Biosciences’ medicine Vykat XR. The treatment has been linked to sev…
  endpoints · 1mo ago
• Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
  Reports of seven deaths in patients who had taken Neurocrine Biosciences’ Vykat and the official termination of Aardvark Therapeutics’ Phase 3 trial after cardiac complications marked a tough day f…
  biospace · 1mo ago
• STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
  Eli Lilly filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide
  stat · 1mo ago
• STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say
  A newly approved drug for Prader-Willi syndrome, a rare disease that causes an insatiable desire to eat, may be tied to a series of patient deaths, experts say.
  stat · 1mo ago
• Novo’s late-stage IL-6 stumble shakes inflammation space
  Novo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week’s Phase 3 failure dashed not just the Danish pharma’s…
  biospace · 2mo ago